These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 27467881)

  • 1. The use of non-economic criteria in pricing and reimbursement decisions in Central and Eastern Europe: issues, trends and recommendations.
    Kolasa K; Kalo Z; Zah V
    Expert Rev Pharmacoecon Outcomes Res; 2016 Aug; 16(4):483-8. PubMed ID: 27467881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HTA and decision-making processes in Central, Eastern and South Eastern Europe: Results from a survey.
    García-Mochón L; Espín Balbino J; Olry de Labry Lima A; Caro Martinez A; Martin Ruiz E; Pérez Velasco R
    Health Policy; 2019 Feb; 123(2):182-190. PubMed ID: 28420539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of health technology assessment in the process of implementation of the EU Transparency Directive: relevant experience from Central Eastern European countries.
    Kolasa K; Kalo Z; Zah V; Dolezal T
    Expert Rev Pharmacoecon Outcomes Res; 2012 Jun; 12(3):283-7. PubMed ID: 22812552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quo Vadis HTA for Medical Devices in Central and Eastern Europe? Recommendations to Address Methodological Challenges.
    Daubner-Bendes R; Kovács S; Niewada M; Huic M; Drummond M; Ciani O; Blankart CR; Mandrik O; Torbica A; Yfantopoulos J; Petrova G; Holownia-Voloskova M; Taylor RS; Al M; Piniazhko O; Lorenzovici L; Tarricone R; Zemplényi A; Kaló Z
    Front Public Health; 2020; 8():612410. PubMed ID: 33490024
    [No Abstract]   [Full Text] [Related]  

  • 5. Pricing and reimbursement frameworks in Central Eastern Europe: a decision tool to support choices.
    Kolasa K; Kalo Z; Hornby E
    Expert Rev Pharmacoecon Outcomes Res; 2015 Feb; 15(1):145-55. PubMed ID: 24964864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries.
    Zelei T; Molnár MJ; Szegedi M; Kaló Z
    Orphanet J Rare Dis; 2016 Jun; 11(1):72. PubMed ID: 27259284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HTA Implementation Roadmap in Central and Eastern European Countries.
    Kaló Z; Gheorghe A; Huic M; Csanádi M; Kristensen FB
    Health Econ; 2016 Feb; 25 Suppl 1(Suppl Suppl 1):179-92. PubMed ID: 26763688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identifying and Revealing the Importance of Decision-Making Criteria for Health Technology Assessment: A Retrospective Analysis of Reimbursement Recommendations in Ireland.
    Schmitz S; McCullagh L; Adams R; Barry M; Walsh C
    Pharmacoeconomics; 2016 Sep; 34(9):925-37. PubMed ID: 27034245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variation in Health Technology Assessment and Reimbursement Processes in Europe.
    Akehurst RL; Abadie E; Renaudin N; Sarkozy F
    Value Health; 2017 Jan; 20(1):67-76. PubMed ID: 28212972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trends and determinants in reimbursement decision-making in Poland in the years 2013-2015.
    Kawalec P; Malinowski KP; Trąbka W
    Expert Rev Pharmacoecon Outcomes Res; 2018 Apr; 18(2):197-205. PubMed ID: 28952400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A DECADE OF HEALTH TECHNOLOGY ASSESSMENT IN POLAND.
    Lipska I; McAuslane N; Leufkens H; Hövels A
    Int J Technol Assess Health Care; 2017 Jan; 33(3):350-357. PubMed ID: 28720170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Navigating joint HTA, procurement, and fair pricing: evidence-based insights and practical recommendations - A meeting report from ISPOR regional conference in Warsaw, 2019.
    Inotai A; Németh B
    Expert Rev Pharmacoecon Outcomes Res; 2019 Aug; 19(4):379-381. PubMed ID: 31159614
    [No Abstract]   [Full Text] [Related]  

  • 13. Recommendations for patient involvement in health technology assessment in Central and Eastern European countries.
    Jakab I; Dimitrova M; Houÿez F; Bereczky T; Fövényes M; Maravic Z; Belina I; Andriciuc C; Tóth K; Piniazhko O; Hren R; Gutierrez-Ibarluzea I; Czech M; Tesar T; Niewada M; Lorenzovici L; Kamusheva M; Manova M; Savova A; Mitkova Z; Tachkov K; Németh B; Petykó ZI; Dawoud D; Delnoij D; Knies S; Goettsch W; Kaló Z
    Front Public Health; 2023; 11():1176200. PubMed ID: 37465169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmaceutical Regulation in Central and Eastern European Countries: A Current Review.
    Kawalec P; Tesar T; Vostalova L; Draganic P; Manova M; Savova A; Petrova G; Rugaja Z; Männik A; Sowada C; Stawowczyk E; Harsanyi A; Inotai A; Turcu-Stiolica A; Gulbinovič J; Pilc A
    Front Pharmacol; 2017; 8():892. PubMed ID: 29326583
    [No Abstract]   [Full Text] [Related]  

  • 15. Health Preference Research in Europe: A Review of Its Use in Marketing Authorization, Reimbursement, and Pricing Decisions-Report of the ISPOR Stated Preference Research Special Interest Group.
    Marsh K; van Til JA; Molsen-David E; Juhnke C; Hawken N; Oehrlein EM; Choi YC; Duenas A; Greiner W; Haas K; Hiligsmann M; Hockley KS; Ivlev I; Liu F; Ostermann J; Poder T; Poon JL; Muehlbacher A
    Value Health; 2020 Jul; 23(7):831-841. PubMed ID: 32762984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pitfalls in reimbursement decisions for oncology drugs in South Korea: need for addressing the ethical dimensions in technology assessment.
    Cho E; Park EC; Kang MS
    Asian Pac J Cancer Prev; 2013; 14(6):3785-92. PubMed ID: 23886183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health technology assessment in Poland, the Czech Republic, Hungary, Romania and Bulgaria.
    Gulácsi L; Rotar AM; Niewada M; Löblová O; Rencz F; Petrova G; Boncz I; Klazinga NS
    Eur J Health Econ; 2014 May; 15 Suppl 1():S13-25. PubMed ID: 24832832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An equity framework for health technology assessments.
    Culyer AJ; Bombard Y
    Med Decis Making; 2012; 32(3):428-41. PubMed ID: 22065143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transferability of National Institute for Health and Clinical Excellence recommendations for pharmaceutical therapies in oncology to Central-Eastern European countries.
    Kaló Z; Landa K; Doležal T; Vokó Z
    Eur J Cancer Care (Engl); 2012 Jul; 21(4):442-9. PubMed ID: 22510226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reimbursement of biosimilars in Poland: is there a link to health technology assessment?
    Neumann D; Jabłecka A
    Expert Rev Pharmacoecon Outcomes Res; 2016 Dec; 16(6):781-792. PubMed ID: 26768654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.